comparemela.com

Results from the 24-week extension period of the phase 2b ENLIVEN trial showed sustained improvements in liver fat, fibrosis, and inflammation among those treated with 30 mg weekly and 44 mg biweekly pegozafermin.

Related Keywords

,Hank Mansbach ,Drug Administration ,Breakthrough Therapy ,Announces New Positive Long Term Data ,Nonalcoholic Steatohepatitis ,Granted Breakthrough Therapy Designation ,Nash ,Nafld ,Nonalcoholic Fatty Liver Disease ,Phase 2b ,Study ,Trial ,Extension ,Enliven ,Pegozafermin ,Fibrosis ,Liver ,Inflammation ,Liver Fat ,Fgf21 ,Glp 1 Therapy ,Cirrhosis ,

© 2025 Vimarsana

comparemela.com © 2020. All Rights Reserved.